Corticosteroids as an adjunct to tuberculosis therapy

References

• Global tuberculosis report 22nd edition. Geneva: World Health Organisation; 2017.
   Google Scholar
• Wilkinson RJ. Host-directed therapies against tuberculosis. Lancet Respir Med. 2014;2(2):85–87.
   PubMed Web of Science ®Google Scholar
• Critchley JA, Young F, Orton L, et al. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(3):223–237.
   PubMed Web of Science ®Google Scholar
• Smego RA, Ahmed N. A systematic review of the adjunctive use of systemic corticosteroids for pulmonary tuberculosis. Int J Tuberc Lung Dis. 2003;7(3):208–213.
   PubMed Web of Science ®Google Scholar
• Critchley JA, Orton LC, Pearson F. Adjunctive steroid therapy for managing pulmonary tuberculosis. Cochrane Database Syst Rev. 2014;11:CD011370.
   Google Scholar
• Tuberculosis Research Centre. Study of chemotherapy regimens of 5 and 7 months’ duration and the role of corticosteroids in the treatment of sputum-positive patients with pulmonary tuberculosis in South India. Tubercle. 1983;64(2):73–91.
   PubMedGoogle Scholar
• Toppet M, Malfroot A, Derde MP, et al. Corticosteroids in primary tuberculosis with bronchial obstruction. Arch Dis Child. 1990;65(11):1222–1226.
   PubMed Web of Science ®Google Scholar
• Park IW, Choi BW, Hue SH. Prospective study of corticosteroid as an adjunct in the treatment of endobronchial tuberculosis in adults. Respirology. 1997;2(4):275–281.
   PubMedGoogle Scholar
• Bilaceroglu S, Perim K, Buyuksirin M, et al. Prednisolone: a beneficial and safe adjunct to antituberculosis treatment? A randomized controlled trial. Int J Tuberc Lung Dis. 1999;3(1):47–54.
   PubMed Web of Science ®Google Scholar
• Mayanja-Kizza H, Jones-Lopez E, Okwera A. et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a Phase 2 clinical trial in Uganda. J Infect Dis. 2005;191(6):856–865.
   PubMed Web of Science ®Google Scholar
• Yang JY, Han M, Koh Y, et al. Effects of corticosteroids on critically Ill pulmonary tuberculosis patients with acute respiratory failure: a propensity analysis of mortality. Clin Infect Dis. 2016;63(11):1449–1455.
   PubMed Web of Science ®Google Scholar
• Thuong NTT, Heemskerk D, Tram TTB, et al. Leukotriene A4 Hydrolase genotype and HIV infection influence intracerebral inflammation and survival from tuberculous meningitis. J Infect Dis. 2017;215(7):1020–1028.
   PubMed Web of Science ®Google Scholar
• O’Toole RD, Thornton GF, Mukherjee MK, et al. Dexamethasone in tuberculous meningitis. Relationship of cerebrospinal fluid effects to therapeutic efficacy. Ann Intern Med. 1969;70(1):39–48.
   PubMed Web of Science ®Google Scholar
• Girgis NI, Farid Z, Kilpatrick ME, et al. Dexamethasone adjunctive treatment for tuberculous meningitis. Pediatr Infect Dis J. 1991;10(3):179–183.
   PubMed Web of Science ®Google Scholar
• Kumarvelu S, Prasad K, Khosla A, et al. Randomized controlled trial of dexamethasone in tuberculous meningitis. Tuber Lung Dis. 1994;75(3):203–207.
   PubMedGoogle Scholar
• Chotmongkol V, Jitpimolmard S, Thavornpitak Y. Corticosteroid in tuberculous meningitis. J Med Assoc Thai. 1996;79(2):83–90.
   PubMedGoogle Scholar
• Schoeman JF, Van Zyl LE, Laubscher JA, et al. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997;99(2):226–231.
   PubMed Web of Science ®Google Scholar
• Thwaites GE, Nguyen DB, Nguyen HD. et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351(17):1741–1751.
   PubMed Web of Science ®Google Scholar
• Malhotra HS, Garg RK, Singh MK, et al. Corticosteroids (dexamethasone versus intravenous methylprednisolone) in patients with tuberculous meningitis. Ann Trop Med Parasitol. 2009;103(7):625–634.
   PubMed Web of Science ®Google Scholar
• Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4:CD002244.
   PubMedGoogle Scholar
• Torok ME, Nguyen DB, Tran TH, et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One. 2011;6(12):e27821.
   PubMed Web of Science ®Google Scholar
• Meintjes G, Wilkinson RJ, Morroni C. et al. Randomized placebo-controlled trial of prednisone for paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome. Aids. 2010;24(15):2381–2390.
   PubMed Web of Science ®Google Scholar
• Marais S, Lai RPJ, Wilkinson KA, et al. Inflammasome activation underlying central nervous system deterioration in HIV-associated tuberculosis. J Infect Dis. 2017;215(5):677–686.
   PubMed Web of Science ®Google Scholar
• Pasipanodya JG, Mubanga M, Ntsekhe M, et al. Tuberculous pericarditis is multibacillary and bacterial burden drives high mortality. EBioMedicine. 2015;2(11):1634–1639.
   PubMed Web of Science ®Google Scholar
• Ntsekhe M, Matthews K, Syed FF, et al. Prevalence, hemodynamics, and cytokine profile of effusive-constrictive pericarditis in patients with tuberculous pericardial effusion. PLoS One. 2013;8(10):e77532.
   PubMed Web of Science ®Google Scholar
• Syed FF, Mayosi BM. A modern approach to tuberculous pericarditis. Prog Cardiovasc Dis. 2007;50(3):218–236.
   PubMed Web of Science ®Google Scholar
• Pandie S, Peter JG, Kerbelker ZS, et al. Diagnostic accuracy of quantitative PCR (Xpert MTB/RIF) for tuberculous pericarditis compared to adenosine deaminase and unstimulated interferon-gamma in a high burden setting: a prospective study. BMC Med. 2014;12:101.
   PubMed Web of Science ®Google Scholar
• Ntsekhe M, Mayosi BM. Tuberculous pericarditis with and without HIV. Heart Fail Rev. 2013;18(3):367–373.
   PubMed Web of Science ®Google Scholar
• Mayosi BM, Burgess LJ, Doubell AF. Tuberculous pericarditis. Circulation. 2005;112(23):3608–3616.
   PubMed Web of Science ®Google Scholar
• Ntsekhe M, Wiysonge C, Volmink JA, et al. Adjuvant corticosteroids for tuberculous pericarditis: promising, but not proven. QJM. 2003;96(8):593–599.
   PubMed Web of Science ®Google Scholar
• Strang JI, Kakaza HH, Gibson DG, et al. Controlled trial of prednisolone as adjuvant in treatment of tuberculous constrictive pericarditis in Transkei. Lancet. 1987;2(8573):1418–1422.
   PubMed Web of Science ®Google Scholar
• Strang JI, Nunn AJ, Johnson DA, et al. Management of tuberculous constrictive pericarditis and tuberculous pericardial effusion in Transkei: results at 10 years follow-up. QJM. 2004;97(8):525–535.
   PubMed Web of Science ®Google Scholar
• Reuter H, Burgess LJ, Louw VJ, et al. The management of tuberculous pericardial effusion: experience in 233 consecutive patients. Cardiovasc J S Afr. 2007;18(1):20–25.
   PubMedGoogle Scholar
• Mayosi BM, Ntsekhe M, Bosch J. et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med. 2014;371(12):1121–1130.
   PubMed Web of Science ®Google Scholar
• Wiysonge CS, Ntsekhe M, Thabane L. et al. Interventions for treating tuberculous pericarditis. Cochrane Database Syst Rev. 2017;9:CD000526.
   PubMedGoogle Scholar
• Keidan SE, Todd RM. Triamcinolone in primary pulmonary tuberculosis. A controlled trial. Lancet. 1961;2(7214):1224–1227.
   PubMedGoogle Scholar
• Nemir RL, Cardona J, Lacoius A, et al. Prednisone therapy as an adjunct in the treatment of lymph node-bronchial tuberculosis in childhood. A double-blind study. Am Rev Respir Dis. 1963;88:189–198.
   PubMed Web of Science ®Google Scholar
• Bunkar ML, Agnihotri SP, Gupta PR, et al. Add-on prednisolone in the management of cervical lymph node tuberculosis. Indian J Tuberc. 2016;63(2):96–99.
   PubMedGoogle Scholar
• Lee CH, Wang WJ, Lan RS, et al. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest. 1988;94(6):1256–1259.
   PubMed Web of Science ®Google Scholar
• Wyser C, Walzl G, Smedema JP, et al. Corticosteroids in the treatment of tuberculous pleurisy. A double-blind, placebo-controlled, randomized study. Chest. 1996;110(2):333–338.
   PubMed Web of Science ®Google Scholar
• Elliott AM, Luzze H, Quigley MA. et al. A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis. 2004;190(5):869–878.
   PubMed Web of Science ®Google Scholar
• Singh MM, Bhargava AN, Jain KP. Tuberculous peritonitis. An evaluation of pathogenetic mechanisms, diagnostic procedures and therapeutic measures. N Engl J Med. 1969;281(20):1091–1094.
   PubMed Web of Science ®Google Scholar
• Alrajhi AA, Halim MA, al-Hokail A, et al. Corticosteroid treatment of peritoneal tuberculosis. Clin Infect Dis. 1998;27(1):52–56.
   PubMed Web of Science ®Google Scholar
• Hawkey CR, Yap T, Pereira J, et al. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clin Infect Dis. 2005;40(9):1368–1371.
   PubMed Web of Science ®Google Scholar
• Lai RP, Meintjes G, Wilkinson RJ. HIV-1 tuberculosis-associated immune reconstitution inflammatory syndrome. Semin Immunopatho. 2016;38(2):185–198.
   PubMed Web of Science ®Google Scholar
• Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis. 2008;8(8):516–523.
   PubMed Web of Science ®Google Scholar
• Namale PE, Abdullahi LH, Fine S, et al. Paradoxical TB-IRIS in HIV-infected adults: a systematic review and meta-analysis. Future Microbiol. 2015;10(6):1077–1099.
   PubMed Web of Science ®Google Scholar
• Cheng SL, Wang HC, Yang PC. Paradoxical response during anti-tuberculosis treatment in HIV-negative patients with pulmonary tuberculosis. Int J Tuberc Lung Dis. 2007;11(12):1290–1295.
   PubMed Web of Science ®Google Scholar
• Yang CH, Chen KJ, Tsai JJ, et al. The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study. BMC Infect Dis. 2014;14:304.
   PubMed Web of Science ®Google Scholar
• Meintjes G, Skolimowska KH, Wilkinson KA, et al. Corticosteroid-modulated immune activation in the tuberculosis immune reconstitution inflammatory syndrome. Am J Respir Crit Care Med. 2012;186(4):369–377.
   PubMed Web of Science ®Google Scholar
• Tadokera R, Meintjes G, Skolimowska KH, et al. Hypercytokinaemia accompanies HIV-tuberculosis immune reconstitution inflammatory syndrome. Eur Resp J. 2011;37(5):1248–1259.
   PubMed Web of Science ®Google Scholar
• Marais S, Meintjes G, Pepper DJ. et al. Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2013;56(3):450–460.
   PubMed Web of Science ®Google Scholar
• Marais S, Wilkinson KA, Lesosky M, et al. Neutrophil-associated central nervous system inflammation in tuberculous meningitis immune reconstitution inflammatory syndrome. Clin Infect Dis. 2014;59(11):1638–1647.
   PubMed Web of Science ®Google Scholar
• Simmons CP, Thwaites GE, Quyen NT, et al. The clinical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J Immunol. 2005;175(1):579–590.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med. 2010;362(8):697–706.
   PubMed Web of Science ®Google Scholar
• Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med. 2011;365(16):1471–1481.
   PubMed Web of Science ®Google Scholar
• Luetkemeyer AF, Havlir DV, Currier JS. Complications of HIV disease and antiretroviral therapy. Top Antivir Med. 2011;19(2):58–68.
   PubMedGoogle Scholar
• Edwards OM, Courtenay-Evans RJ, Galley JM, et al. Changes in cortisol metabolism following rifampicin therapy. Lancet. 1974;2(7880):548–551.
   PubMed Web of Science ®Google Scholar
• Bergrem H, Refvem OK. Altered prednisolone pharmacokinetics in patients treated with rifampicin. Acta Med Scand. 1983;213(5):339–343.
   PubMedGoogle Scholar
• Sarma GR, Kailasam S, Nair NG, et al. Effect of prednisolone and rifampin on isoniazid metabolism in slow and rapid inactivators of isoniazid. Antimicrob Agents Chemother. 1980;18(5):661–666.
   PubMed Web of Science ®Google Scholar
• Wagay AR, Singhal KC, Bhargava R. Alteration in the levels of pyrazinamide in pleural fluid following simultaneous administration of prednisoline in patients of tubercular pleural effusion. Indian J Physiol Pharmacol. 1990;34(4):259–262.
   PubMedGoogle Scholar
• McAllister WA, Thompson PJ, Al-Habet SM, et al. Rifampicin reduces effectiveness and bioavailability of prednisolone. Br Med J (Clin Res Ed). 1983;286(6369):923–925.
   PubMedGoogle Scholar
• Pratt WB, Toft DO. Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev. 1997;18(3):306–360.
   PubMed Web of Science ®Google Scholar
• Gallo LI, Ghini AA, Piwien Pilipuk G, et al. Differential recruitment of tetratricorpeptide repeat domain immunophilins to the mineralocorticoid receptor influences both heat-shock protein 90-dependent retrotransport and hormone-dependent transcriptional activity. Biochem. 2007;46(49):14044–14057.
   PubMed Web of Science ®Google Scholar
• Roth SY, Denu JM, Allis CD. Histone acetyltransferases. Annu Rev Biochem. 2001;70:81–120.
   PubMed Web of Science ®Google Scholar
• Chen Q, Chen T, Xu Y, et al. Steroid receptor coactivator 3 is required for clearing bacteria and repressing inflammatory response in Escherichia coli-induced septic peritonitis. J Immunol. 2010;185(9):5444–5452.
   PubMed Web of Science ®Google Scholar
• Dostert A, Heinzel T. Negative glucocorticoid receptor response elements and their role in glucocorticoid action. Curr Pharm Des. 2004;10(23):2807–2816.
   PubMed Web of Science ®Google Scholar
• Nissen RM, Yamamoto KR. The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev. 2000;14(18):2314–2329.
   PubMed Web of Science ®Google Scholar
• De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol. 2000;109(1):16–22.
   PubMed Web of Science ®Google Scholar
• Ray A, Prefontaine KE. Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A. 1994;91(2):752–756.
   PubMed Web of Science ®Google Scholar
• Scheinman RI, Gualberto A, Jewell CM, et al. Characterization of mechanisms involved in transrepression of NF-kappa B by activated glucocorticoid receptors. Mol Cell Biol. 1995;15(2):943–953.
   PubMed Web of Science ®Google Scholar
• Reichardt HM, Tuckermann JP, Gottlicher M, et al. Repression of inflammatory responses in the absence of DNA binding by the glucocorticoid receptor. EMBO J. 2001;20(24):7168–7173.
   PubMed Web of Science ®Google Scholar
• Adcock IM, Nasuhara Y, Stevens DA, et al. Ligand-induced differentiation of glucocorticoid receptor (GR) trans-repression and transactivation: preferential targetting of NF-kappaB and lack of I-kappaB involvement. Br J Pharmacol. 1999;127(4):1003–1011.
   PubMed Web of Science ®Google Scholar
• Sheppard KA, Phelps KM, Williams AJ, et al. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem. 1998;273(45):29291–29294.
   PubMed Web of Science ®Google Scholar
• Wadgaonkar R, Phelps KM, Haque Z, et al. CREB-binding protein is a nuclear integrator of nuclear factor-kappaB and p53 signaling. J Biol Chem. 1999;274(4):1879–1882.
   PubMed Web of Science ®Google Scholar
• McKay LI, Cidlowski JA. CBP (CREB binding protein) integrates NF-kappaB (nuclear factor-kappaB) and glucocorticoid receptor physical interactions and antagonism. Mol Endocrinol. 2000;14(8):1222–1234.
   PubMedGoogle Scholar
• Sutter-Dub MT. Rapid non-genomic and genomic responses to progestogens, estrogens, and glucocorticoids in the endocrine pancreatic B cell, the adipocyte and other cell types. Steroids. 2002;67(2):77–93.
   PubMed Web of Science ®Google Scholar
• Hafezi-Moghadam A, Simoncini T, Yang Z, et al. Acute cardiovascular protective effects of corticosteroids are mediated by non-transcriptional activation of endothelial nitric oxide synthase. Nat Med. 2002;8(5):473–479.
   PubMed Web of Science ®Google Scholar
• Wiper-Bergeron N, Wu D, Pope L, et al. Stimulation of preadipocyte differentiation by steroid through targeting of an HDAC1 complex. EMBO J. 2003;22(9):2135–2145.
   PubMed Web of Science ®Google Scholar
• Nykjaer A, Dragun D, Walther D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 1999;96(4):507–515.
   PubMed Web of Science ®Google Scholar
• Oren I, Fleishman SJ, Kessel A, et al. Free diffusion of steroid hormones across biomembranes: a simplex search with implicit solvent model calculations. Biophys J. 2004;87(2):768–779.
   PubMed Web of Science ®Google Scholar
• Wang C, Liu Y, Cao JM. G protein-coupled receptors: extranuclear mediators for the non-genomic actions of steroids. Int J Mol Sci. 2014;15(9):15412–15425.
   PubMed Web of Science ®Google Scholar
• Matasic R, Dietz AB, Vuk-Pavlovic S. Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J Leukoc Biol. 1999;66(6):909–914.
   PubMed Web of Science ®Google Scholar
• Raker VK, Domogalla MP, Steinbrink K. Tolerogenic dendritic cells for regulatory T cell induction in man. Front Immunol. 2015;6:569.
   PubMed Web of Science ®Google Scholar
• Barczyk K, Ehrchen J, Tenbrock K, et al. Glucocorticoids promote survival of anti-inflammatory macrophages via stimulation of adenosine receptor A3. Blood. 2010;116(3):446–455.
   PubMed Web of Science ®Google Scholar
• Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest. 1998;101(4):890–898.
   PubMed Web of Science ®Google Scholar
• Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann NY Acad Sci. 2004;1024:138–146.
   PubMed Web of Science ®Google Scholar
• Hawrylowicz CM. Regulatory T cells and IL-10 in allergic inflammation. J Exp Med. 2005;202(11):1459–1463.
   PubMed Web of Science ®Google Scholar
• Tobin DM, Roca FJ, Oh SF. et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell. 2012;148(3):434–446.
   PubMed Web of Science ®Google Scholar
• Mayosi BM, Ntsekhe M, Bosch J, et al. Rationale and design of the investigation of the management of pericarditis (IMPI) trial: a 2 × 2 factorial randomized double-blind multicenter trial of adjunctive prednisolone and Mycobacterium w immunotherapy in tuberculous pericarditis. Am Heart J. 2013;165(2):109–115e103.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services. p. J14. [cited 2018 Jul 27]. Available from: https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
   Google Scholar
• Universal antiretroviral therapy (ART) for all HIV-infected TB patients. World Health Organization. [cited 2018 Jul 27]. Available from: http://www.who.int/hiv/topics/tb/art_hivpatients/en/
   Google Scholar
• European AIDS Clinical Society: Guidelines. Version 9. 2017 Oct [cited 2018 Jul 27]. Available from: http://www.eacsociety.org/files/guidelines_9.0-english.pdf
   Google Scholar
• Prevention of Mother- to- Child Transmission of HIV (PMTCT). Children, adolescents and adults. (2018 amended version). [cited 2018 Jul 27]. Available from: https://www.westerncape.gov.za/assets/departments/health/wc_hiv_consolidated_guidelines_march_2018_0.pdf
   Google Scholar
• Singh AK, Malhotra HS, Garg RK, et al. Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis. BMC Infect Dis. 2016;16:306.
   PubMed Web of Science ®Google Scholar
• Boland EW. Clinical comparison of the newer anti-inflammatory corticosteroids. Ann Rheum Dis. 1962;21:176–187.
   PubMed Web of Science ®Google Scholar